Correct Success: OncoSec Medical Closes $42.0 Million Public Offering of Common Stock

PENNINGTON, N.J. and SAN DIEGO, Jan. 25, 2021 /PRNewswire/ — OncoSec Medical Integrated (NASDAQ:ONCS) (the “Firm” or “OncoSec”), a late-stage biotechnology firm centered on designing, creating and commercializing modern therapies and proprietary medical approaches to stimulate and information an anti-tumor immune response for the remedy of most cancers as we speak introduced the closing of a beforehand introduced underwritten public providing of seven,711,284 shares of its frequent inventory at a value of $5.45 per share. The gross proceeds to OncoSec from the providing, earlier than deducting underwriting reductions, commissions and different providing bills payable by OncoSec, had been roughly $42 million.

BTIG, LLC acted as sole book-running supervisor for the providing. A.G.P./Alliance World Companions and ThinkEquity, a division of Fordham Monetary Administration, Inc. acted as lead managers for the providing, and Maxim Group LLC and Dawson James Securities, Inc. acted as co-managers for the providing

OncoSec intends to make use of the web proceeds from this providing for (i) scientific, regulatory, manufacturing and, if and when accredited, potential industrial actions of its product candidates; (ii) scientific improvement of the corporate’s product candidates; (iii) analysis and improvement actions; (iv) potential acquisitions and in-licensing; and (v) different common company functions.

OncoSec has filed a closing prospectus complement and accompanying base prospectus to its efficient shelf registration assertion on Type S-3 (File No. 333-233447), and the associated registration assertion on Type S-3 (File No. 333-252281), filed underneath Rule 462(b) of the Securities Act of 1933, as amended, with the U.S. Securities and Change Fee (“SEC”) for the general public providing of its frequent inventory. Copies of the ultimate prospectus complement and the accompanying base prospectus relating to those securities might also be obtained by contacting BTIG, LLC 65 East 55^th Avenue, New York, NY, 10022, or by phone at (212) 593-7555 or by e-mail at equitycapitalmarkets@btig.com.

The providing of those securities is being made underneath an efficient shelf registration assertion on file with the SEC. This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase, nor shall there be any sale of those securities in any state or jurisdiction during which such supply, solicitation or sale can be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.

About TAVO^™
OncoSec’s gene remedy expertise combines TAVO^™ (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (“IL-12”), with an intra-tumoral electroporation gene supply platform to realize endogenous IL-12 manufacturing within the tumor microenvironment that allows the immune system to focus on and assault tumors all through the physique. TAVO has demonstrated a neighborhood and systemic anti-tumor response in a number of scientific trials, together with the pivotal Section 2b trial KEYNOTE-695 for metastatic melanoma and the KEYNOTE-890 Section 2 trial in triple adverse breast most cancers (“TNBC”). TAVO has acquired each Orphan Drug and Quick-Monitor Designation by the U.S. Meals & Drug Administration for the remedy of metastatic melanoma.

About OncoSec Medical Integrated
OncoSec Medical Integrated (the “Firm,” “OncoSec,” “we” or “our”) is a late-stage biotechnology firm centered on creating cytokine-based intratumoral immunotherapies to stimulate the physique’s immune system to focus on and assault most cancers. OncoSec’s lead immunotherapy investigational product candidate – TAVO (tavokinogene telseplasmid) – permits the intratumoral supply of DNA-based interleukin-12 (“IL-12”), a naturally occurring protein with immune-stimulating features. The expertise, which employs electroporation, is designed to supply a managed, localized expression of IL-12 within the tumor microenvironment, enabling the immune system to focus on and assault tumors all through the physique. OncoSec has constructed a deep and numerous scientific pipeline using TAVO as a possible remedy for a number of most cancers indications both as a monotherapy or together with main checkpoint inhibitors; with the latter probably enabling OncoSec to deal with an ideal unmet medical want in oncology: anti-PD-1 non-responders. Outcomes from just lately accomplished scientific research of TAVO have demonstrated a neighborhood immune response, and subsequently, a systemic impact as both a monotherapy or mixture remedy method together with an appropriate security profile, warranting additional improvement. Along with TAVO, OncoSec is figuring out and creating new DNA-encoded therapeutic candidates and tumor indications to be used with its new Visceral Lesion Applicator, to focus on deep visceral lesions, comparable to liver, lung or pancreatic lesions. For extra data, please go to www.oncosec.com.

TAVO™ is a trademark of OncoSec Medical Integrated.

Danger Components and Ahead-Trying Statements
This launch, in addition to different data supplied now and again by the Firm or its staff, could include forward-looking statements, together with statements concerning the anticipated use of proceeds, that contain numerous dangers and uncertainties that would trigger precise outcomes to vary materially from these anticipated within the forward-looking statements. Ahead-looking statements present the Firm’s present beliefs, expectations and intentions concerning future occasions and contain dangers, uncertainties (a few of that are past the Firm’s management) and assumptions. For these statements, we declare the safety of the protected harbor for forward-looking statements contained within the Non-public Securities Litigation Reform Act of 1995. You possibly can establish forward-looking statements by the truth that they don’t relate strictly to historic or present info. These statements could embody phrases comparable to “anticipate,” “consider,” “may,” “estimate,” “count on,” “intend,” “could,” “plan,” “potential,” “ought to,” “will” and “would” and comparable expressions (together with the adverse of those phrases). Though we consider that expectations mirrored within the forward- trying statements are cheap, we can’t assure future outcomes, ranges of exercise, efficiency or achievements. The Firm intends these forward-looking statements to talk solely on the time they’re revealed on or as in any other case specified and doesn’t undertake to replace or revise these statements as extra data turns into obtainable, besides as required underneath federal securities legal guidelines and the principles and laws of the Securities Change Fee (“SEC”). Particularly, you ought to be conscious that the success and timing of our scientific trials, together with security and efficacy of our product candidates, affected person accrual, surprising or anticipated security occasions, the influence of COVID-19 on the provision of our candidates or the initiation or completion of scientific trials and the usability of knowledge generated from our trials could differ and will not meet our estimated timelines. Please consult with the danger components and different cautionary statements supplied within the Firm’s Annual Report on Type 10-Ok for the fiscal 12 months ended July 31, 2020 and subsequent periodic and present reviews filed with the SEC (every of which might be discovered on the SEC’s web site www.sec.gov), in addition to different components described now and again within the Firm’s filings with the SEC.

Firm Contact
Kim Jaffe, Ph.D.
Assistant Vice President, Enterprise Growth & Operations
+1-858-210-7330
kjaffe@oncosec.com

Media Contact
Patrick Bursey
LifeSci Communications
+1-646-970-4688
pbursey@lifescicomms.com